Hoth Therapeutics, Inc.

NasdaqCM:HOTH Stock Report

Market Cap: US$15.7m

Hoth Therapeutics Management

Management criteria checks 2/4

Hoth Therapeutics' CEO is Robb Knie, appointed in May 2017, has a tenure of 8.58 years. total yearly compensation is $1.23M, comprised of 36.7% salary and 63.3% bonuses, including company stock and options. directly owns 3.53% of the company’s shares, worth $552.86K. The average tenure of the management team and the board of directors is 6.8 years and 5.7 years respectively.

Key information

Robb Knie

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage36.68%
CEO tenure8.6yrs
CEO ownership3.5%
Management average tenure6.8yrs
Board average tenure5.7yrs

Recent management updates

Recent updates

Hoth Therapeutics (NASDAQ: HOTH): Small-Cap Biotech Pairing Clinical Breakthroughs with AI Innovation

Sep 08
Hoth Therapeutics (NASDAQ: HOTH): Small-Cap Biotech Pairing Clinical Breakthroughs with AI Innovation

Weekly Picks: 💸 A fintech heavyweight with even more upside potential and 2 more picks

Sep 05
Weekly Picks: 💸 A fintech heavyweight with even more upside potential and 2 more picks

100% Patient Improvement in trial puts this $16M Biotech on the radar

Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.

Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury

Sep 20

Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule

Jun 29

Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation

Nov 12
Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation

We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate

Jun 10
We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate

CEO Compensation Analysis

How has Robb Knie's remuneration changed compared to Hoth Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$12m

Jun 30 2025n/an/a

-US$10m

Mar 31 2025n/an/a

-US$10m

Dec 31 2024US$1mUS$450k

-US$8m

Sep 30 2024n/an/a

-US$8m

Jun 30 2024n/an/a

-US$8m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023US$846kUS$450k

-US$8m

Sep 30 2023n/an/a

-US$10m

Jun 30 2023n/an/a

-US$10m

Mar 31 2023n/an/a

-US$11m

Dec 31 2022US$1mUS$450k

-US$11m

Sep 30 2022n/an/a

-US$11m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$1mUS$400k

-US$14m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$10m

Mar 31 2021n/an/a

-US$10m

Dec 31 2020US$781kUS$350k

-US$7m

Sep 30 2020n/an/a

-US$10m

Jun 30 2020n/an/a

-US$10m

Mar 31 2020n/an/a

-US$9m

Dec 31 2019US$2mUS$350k

-US$8m

Sep 30 2019n/an/a

-US$4m

Jun 30 2019n/an/a

-US$3m

Mar 31 2019n/an/a

-US$3m

Dec 31 2018US$308kUS$250k

-US$2m

Compensation vs Market: Robb's total compensation ($USD1.23M) is above average for companies of similar size in the US market ($USD577.34K).

Compensation vs Earnings: Robb's compensation has increased whilst the company is unprofitable.

CEO

Robb Knie (56 yo)

8.6yrs
Tenure
US$1,226,792
Compensation

Mr. Robb Knie is Founder of Hoth Therapeutics, Inc. Mr. Knie served as the Chief Executive Officer, Chief Financial Officer and Chairman of the Board of Directors of FoxWayne Enterprises Acquisition Corp....

Leadership Team

NamePositionTenureCompensationOwnership
Robb Knie
Founder8.6yrsUS$1.23m3.53%
$ 552.9k
David Briones
Chief Financial Officer6.8yrsno datano data
Hayley Springer
Executive Vice President of Operations3.6yrsno datano data
6.8yrs
Average Tenure

Experienced Management: HOTH's management team is seasoned and experienced (6.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robb Knie
Founder8.6yrsUS$1.23m3.53%
$ 552.9k
Adam Friedman
Member of Scientific Advisory Board8.4yrsno datano data
Mario Lacouture
Member of Scientific Advisory Board4.9yrsno datano data
John Cirrito
Member of Scientific Advisory Board3.9yrsno datano data
David Sarnoff
Independent Director7.3yrsUS$93.36k0.0065%
$ 1.0k
William Weglicki
Member of Scientific Advisory Board6yrsno datano data
Wayne Linsley
Independent Director5.7yrsUS$93.36k0.00086%
$ 134.8
Glenn Cruse
Member of Scientific Advisory Board5.8yrsno datano data
Sergio Traversa
Member of Scientific Advisory Boardno datano datano data
Jeff Pavell
Independent Director3yrsUS$93.36k0.033%
$ 5.1k
Carla Yuede
Member of Scientific Advisory Board3.9yrsno datano data
Christopher Camarra
Independent Directorless than a yearno datano data
5.7yrs
Average Tenure
57yo
Average Age

Experienced Board: HOTH's board of directors are considered experienced (5.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/29 21:38
End of Day Share Price 2025/12/26 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hoth Therapeutics, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertD. Boral Capital LLC.